Newly Elected European Society Of Cardiology President Co-Authored Hundreds Of Papers With Don Poldermans Reply

The ESC today announced that Jeroen Bax, a Dutch cardiologist, will serve as the group’s President Elect for the next two years before becoming President starting in 2016. Bax is a professor of cardiology at Leiden University Medical Center. Bax is also known for his very close collaboration with Don Poldermans, the disgraced Dutch researcher who has been accused of significant and multiple examples of scientific misconduct. … Click here to read the full post on Forbes.      

First Retraction In the Don Poldermans Case Reply

Retraction Watch reports the first formal retraction of a paper by Don Poldermans, the disgraced Dutch cardiovascular researcher. Feringa HH, Elhendy A, Bax JJ, Boersma E, de Jonge R, Schouten O, Karagiannis SE, Schinkel AF, Lindemans J, Poldermans D. Coron Artery Dis. 2006 May;17(3):255-9. Baseline plasma N-terminal pro-B-type natriuretic peptide is associated with the extent of stress-induced myocardial ischemia during dobutamine stress echocardiography. Here is the text of the retraction: Feringa HH, Elhendy A, Bax JJ, Boersma E, de Jonge R, Schouten O, et al. Baseline plasma N-terminal pro-B-type natriuretic peptide is associated with the extent of More…

Scientific Misconduct: From Darwin And Mendel To Poldermans And Matsubara Reply

Responding to recent episodes of scientific misconduct in cardiovascular research involving once prominent cardiovascular researchers, the editor of the European Heart Journal, Thomas Lüscher, has written an editorial discussing the significance of the new cases and placing them in a historical context that includes allegations of scientific misconduct by Mendel and Darwin, among many others. … Poldermans was the first or the senior author in 7 papers published in EHJ. Lüscher writes that the chairman of the Poldermans investigative committee “made it clear that the vast amount of publications led by Poldermans over the last decades made it impossible to assess More…

Embers Of Poldermans Case Still Smoldering Reply

A prominent US cardiologist has rebuked Don Poldermans, the cardiovascular researcher at the center of a research scandal in the Netherlands. As reported here previously, Poldermans was fired for scientific misconduct by the Erasmus Medical Center in Rotterdam, where he had been a professor of medicine and the head of perioperative cardiac care. He was widely published and active in the field, serving as a member of the European Society of Cardiology committee for practice guidelines and as the chairperson of the ESC guidelines on pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. He was also More…

JACC Issues Notice of Concern Over Three Poldermans Papers 2

The editors of the Journal of the American College of Cardiology have issued a “Notice of Concern” over three JACC articles in which Don Poldermans, the disgraced Dutch researcher, served as the first or the last author. The editors relied on the report of the investigation committee at Erasmus Medical Center published in October. In each case the editors have accepted the committee’s finding that although the studies contain numerous examples of scientific “irregularities,” the evidence does not warrant full retractions for the papers. For the first paper, the committee cited numerous irregularities, including  inconsistencies between source documentation More…

Don Poldermans And The Dutch Research Scandal 4

The publication last week of the final report from the Erasmus Medical Center on the Don Poldermans research scandal in the Netherlands ends the first and most explosive chapter of an ugly episode of scientific misconduct. But there are still many important questions regarding scientific integrity and the culture of medical research raised by the case. And one key detail about the case remains– and is likely to remain– unanswered. Did Don Poldermans commit scientific fraud by fabricating data or was he only guilty of the serious but lesser sin of poor or negligent supervision of a More…

Investigation in Poldermans Case Expands to Leiden University Medical Center 1

The investigation in the Dutch scientific misconduct case has now spread to the Leiden University Medical Center, according to media reports in the Netherlands. The case first came to public attention last month when the Erasmus Medical Center in Rotterdam fired  prominent cardiovascular researcher Don Poldermans. (Click here for previous CardioBrief coverage of the case.) A spokesman for LUMC told the Dutch media that the investigation is specifically looking at “a professor who has published frequently” with Poldermans [according to Google Translate], but it may also investigate other Leiden scientists. No names have so far been publicly mentioned, though More…

ESC May Re-Examine Guidelines in Wake of Poldermans Dismissal Reply

In the wake of the dismissal of Don Poldermans from the Erasmus Medical Center due to scientific misconduct (for background see this and this) the European Society of Cardiology has announced that Poldermans has resigned from his position as chairperson of the task force that created the ESC practice guidelines for preoperative cardiac risk assessment and preoperative cardiac management in non-cardiac surgery. The ESC also stated that it is “looking into” the guidelines “in order to decide if these need to be re-examined in the light of recent events.” Here is the ESC statement:  ESC Guidelines are More…

Dutch Investigation Finds Serious Flaws In Influential New England Journal Of Medicine Study Reply

Erasmus Medical Center says it has wrapped up its investigation of Don Poldermans, the disgraced cardiology researcher who was fired for research misconduct. The full extent of the misconduct has never been known, and from an examination of the Erasmus report it appears likely that it never will be known. One major finding– though downplayed in the medical center’s press release– is that the most prestigious and influential publication from the Poldermans’ group, the 1999 publication of the DECREASE 1 study in the New England Journal of Medicine– appears to be riddled with serious problems. … Click here to read More…

Medicine Or Mass Murder? Guideline Based on Discredited Research May Have Caused 800,000 Deaths In Europe Over The Last 5 Years 2

Last summer British researchers provoked concern when they published a paper raising the possibility that by following an established guideline UK doctors may have caused as many as 10,000 deaths each year. Now they have gone a step further and published an estimate that the same guideline may have led to the deaths of as many as 800,00 people in Europe over the last five years. The finding, they write, “is so large that the only context in the last 50 years comes from the largest scale professional failures in the political sphere.” The 800,000 deaths are comparable More…

European Heart Guidelines Based On Disgraced Research May Have Caused Thousands Of Deaths 1

Despite a 2-year-old scandal discrediting key evidence, current guidelines relying on this evidence have not been revised. As a result of physicians following these guidelines, some researchers say, it is possible that thousands of patients may have died each year in the UK alone. It is unlikely that a true understanding of the damage will ever be known. Current European Society of Cardiology guidelines recommend that beta-blockers be given to many patients having surgery for noncardiac reasons to protect the heart during surgery. (US guidelines are somewhat less aggressive in their endorsement of perioperative beta-blockade.) The guidelines, More…

2012 In Review: A Bad Year For Conventional Wisdom 3

This was a really grim year for anyone who thought we had things pretty well figured out. Time and again conventional wisdom was thrown out the window. 2012 forced the cardiology community to reconsider what it thought it knew about HDL cholesterol, platelet function tests, aspirin resistance, triple therapy, IABP, and more. One device company, with a lot of help, did just about everything right when it introduced a radical, highly disruptive new technology. Another device company did just about everything wrong in handling a series of crises. The new generation oral anticoagulants continued to More…

Erasmus Medical Center Releases Final Report On Cardiovascular Research Scandal 2

After an extensive investigation, a large medical center in the Netherlands has confirmed earlier charges of research misconduct against a prominent cardiovascular researcher. On Tuesday, Erasmus MC in Rotterdam released a final report on the scientific integrity of trials conducted by Don Poldermans, a well-known and highly prolific Dutch cardiovascular researcher. The final report contains numerous allegations of scientific misconduct related to the conduct of several clinical trials run by Poldermans at Erasmus MC. Poldermans admits responsibility for some instances of misconduct but also vigorously denies the most serious charges involving scientific fraud. He provided More…

New Perspective on the Dutch Cardiovascular Research Scandal 2

New information and details have  emerged about the cardiovascular research scandal in the Netherlands. One prominent cardiologist with close ties to the central character in the scandal has been cleared of wrongdoing by his institution and a feature magazine article sheds new light on that central character, Don Poldermans. As previously reported here last November, Poldermans was fired for scientific misconduct by the Erasmus Medical Center in Rotterdam. Poldermans had been a professor of medicine and the head of perioperative cardiac care at the Erasmus Medical Center. He was widely published and active in the field, serving More…

2011 in Review: Rivaroxaban, Sapien, Mark Midei, Conflicts of Interest, and Much More 4

Here’s a completely personal review of the past year in cardiology. Please write a comment if you strongly agree, disagree, or think something is missing. Drug of the Year: Rivaroxaban (Xarelto)– Despite a highly negative review from FDA reviewers, rivaroxaban gained FDA approval for the coveted stroke prevention in AF indication. The drug was approved earlier in the year for VTE prevention after surgery. The biggest surprise, though, was rivaroxaban’s success in ACS in the ATLAS ACS TIMI 51 trial, which may well have an important impact on the field for years to come. Rivaroxaban (Xarelto) Gains First More…

More Details Emerge About the Dutch Research Scandal 5

More details have emerged about the research scandal in the Netherlands, in which prominent Erasmus Medical Center cardiovascular researcher Don Poldermans was fired for scientific misconduct. Anonymously leaked portions of a report from the Erasmus Medical Center investigation first appeared on Scribd over the weekend [Editor's note: the Scribd link is no longer working]. Later an executive summary of the report, dated November 16, appeared on the Erasmus website. All the documents are in Dutch. Here is a brief summary, based on help received from Google Translate, Babel Fish, and native Dutch speakers. As previously reported, the More…

Prominent Dutch Cardiovascular Researcher Fired for Scientific Misconduct 7

Updated– Don Poldermans, a well-known researcher in cardiovascular medicine in the Netherlands, has been fired for scientific misconduct by the Erasmus Medical Center in Rotterdam. According to a statement from Erasmus Medical center, an investigation found that Poldermans was careless in collecting the data for his research. In one study it was found that he used patient data without written permission, used fictitious data and that two reports were submitted to conferences which included knowingly unreliable data. Poldermans, according to Erasmus, has accepted the conclusions of the committee and “expressed his regret for his actions,” but said More…